Paper Details

  1. Home
  2. Paper Details

SCREENING OF PROTEASE INHIBITORS RESISTANCE MUTATIONS IN HEPATITIS C VIRUS ISOLATES INFECTING ROMANIAN PATIENTS UNEXPOSED TO TRIPLE THERAPY.

Author: CalistruPetre-Iacob, CeauşuEmanoil, DinuSorin, OprişanGabriela, TârdeilGraţiela

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study detected pre-treatment resistance mutations to boceprevir and telaprevir in hepatitis C virus isolates infecting Romanian patients.
Paper Details　
Original Abstract of the Article :
Although the European recommendations include the use of new antiviral drugs for the treatment of hepatitis C, in Romania the current treatment remains interferon plus ribavirin. First generation viral protease inhibitors (i.e. boceprevir, telaprevir), which have raised the chances of obtaining vira...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/26727849

データ提供：米国国立医学図書館（NLM）

Hepatitis C Virus: A Persistent Foe with New Challenges

The fight against hepatitis C virus (HCV) is an ongoing battle, with new challenges constantly emerging. This study investigates the potential for pre-treatment resistance to protease inhibitors in HCV isolates from Romanian patients. The researchers analyzed the NS3 protease region of HCV isolates from patients who had not been previously treated with protease inhibitors. They discovered the presence of two boceprevir resistance mutations (T54S and V55A) and one telaprevir resistance mutation (T54S). These findings suggest that pre-treatment resistance to protease inhibitors may be a growing concern, potentially impacting the effectiveness of these drugs.

A Shifting Landscape: The Rise of Resistance

This study highlights the ever-evolving nature of HCV. The emergence of pre-treatment resistance to protease inhibitors underscores the importance of monitoring and understanding the genetic diversity of HCV isolates. This knowledge is crucial for developing effective treatment strategies and preventing the spread of resistant strains.

A Call to Action: Adapting Treatment Strategies

This research underscores the need for continued vigilance in the fight against HCV. The emergence of pre-treatment resistance to protease inhibitors emphasizes the importance of adapting treatment strategies to address these challenges. This includes ongoing surveillance of HCV genetic diversity, development of new antiviral agents, and optimization of treatment regimens to minimize the risk of resistance.

Dr.Camel's Conclusion

This study provides a timely reminder of the challenges posed by HCV resistance. The discovery of pre-treatment resistance to protease inhibitors in Romanian patients highlights the need for proactive measures to monitor and address the evolving nature of HCV. Continued research and development are essential to ensure the effectiveness of HCV treatment and minimize the spread of resistant strains.

Date :
  1. Date Completed 2016-02-09
  2. Date Revised 2016-01-05
Further Info :

Pubmed ID

26727849

DOI: Digital Object Identifier

26727849

Related Literature

Article Analysis
・Effects of boceprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.